Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 229Leukemia, Lymphocytic, Chronic, B-Cell 213Leukemia 203Myelodysplastic Syndromes 185Precursor Cell Lymphoblastic Leukemia-Lymphoma 174Lymphoma 148Lymphoma, Non-Hodgkin 142Multiple Myeloma 131Hodgkin Disease 123Lymphoma, Follicular 111Lymphoma, Mantle-Cell 108Lymphoma, Large B-Cell, Diffuse 96Lymphoma, B-Cell, Marginal Zone 89Myeloproliferative Disorders 86Congenital Abnormalities 85Burkitt Lymphoma 85Leukemia, Myelomonocytic, Chronic 77Leukemia, Myelogenous, Chronic, BCR-ABL Positive 75Leukemia, Myeloid, Chronic-Phase 74Leukemia, Myeloid, Accelerated Phase 73Recurrence 63Melanoma 62Lymphoma, Large-Cell, Immunoblastic 61Anemia, Refractory, with Excess of Blasts 60Neoplasms, Plasma Cell 56Waldenstrom Macroglobulinemia 55Primary Myelofibrosis 55Blast Crisis 55Hematologic Neoplasms 45Lymphoma, T-Cell, Cutaneous 42

Interventions

siltuximab 4tocilizumab 3fludarabine 3Cyclophosphamide 3fludarabine phosphate 2Interleukin 1 Receptor Antagonist Protein 2AP 1903 reagent 2talquetamab 1otelixizumab 1obinutuzumab 1lopinavir-ritonavir drug combination 1glofitamab 1axicabtagene ciloleucel 1Piperacillin, Tazobactam Drug Combination 1Oxygen Inhalation Therapy 1Oxaliplatin 1Neuropsychological Tests 1Metoprolol 1Methylprednisolone 1Magnetic Resonance Spectroscopy 1Lopinavir 1Leukapheresis 1Infliximab 1Hydroxychloroquine 1Heparin, Low-Molecular-Weight 1Gemcitabine 1Gelsolin 1Etanercept 1Dexamethasone 1Contrast Media 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Cytokine Release Syndrome × fludarabine phosphate × Clear all
NCT03696784 2025-12-08

Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma

UNC Lineberger Comprehensive Cancer Center

Phase 1 Active not recruiting
19 enrolled
Lymphoid

Cytokine Release Syndrome, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, B-Cell, Neurotoxicity Syndromes

NCT03016377 2025-10-27

Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL

UNC Lineberger Comprehensive Cancer Center

Phase 1/2 Active not recruiting
17 enrolled
LymphoidOther hematologic neoplasm

Cytokine Release Syndrome, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡